Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study
Author:
Publisher
Springer Science and Business Media LLC
Subject
Immunology,Immunology and Allergy,Rheumatology
Link
https://link.springer.com/content/pdf/10.1007/s00296-021-05086-w.pdf
Reference34 articles.
1. Bourne T, Fossati G, Nesbitt A (2008) A PEGylated Fab’ fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. BioDrugs 22:331–337. https://doi.org/10.2165/00063030-200822050-00005
2. Rivkin A (2009) Certolizumab pegol for the management of Crohn’s disease in adults. Clin Ther 31:1158–1176. https://doi.org/10.1016/j.clinthera.2009.06.015
3. Ingegnoli F, Castelli R, Gualtierotti R (2013) Rheumatoid factors: clinical applications. Dis Markers 35:727–734. https://doi.org/10.1155/2013/726598
4. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A et al (2019) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685–699. https://doi.org/10.1136/annrheumdis-2019-216655
5. Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M et al (2019) Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study. Arthritis Res Ther 21:91. https://doi.org/10.1186/s13075-019-1880-4
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. High rheumatoid factor does not diminish efficacy of TNF inhibitors in seropositive JIA;2024-01-24
2. Des titres élevés de facteur rhumatoïde (FR) ont-ils un impact sur la réponse aux anti-TNF ? Comparaison entre certolizumab pegol et adalimumab chez des patients atteints de PR présentant des titres élevés de FR : analyse post-hoc d’une étude de phase IV;Revue du Rhumatisme;2023-12
3. Patterns and determinants of response to novel therapies in juvenile and adult-onset polyarthritis;Rheumatology;2023-09-19
4. Stairway to Heaven: Do head-to-head Trials Indicate a Need for Definite Criteria for Choosing Biologic Drugs in Rheumatoid Arthritis?;Current Rheumatology Reviews;2023-08-03
5. Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post‐hoc analysis of clinical trials;International Journal of Rheumatic Diseases;2023-05-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3